In October 2021, Raynier granted $250,000 to Penn Medicine in support of “Tackling Breast Cancer Recurrence.” The support from the Raynier Institute & Foundation will help fund Dr. Angie DeMichele’s research team for minimal residual disease (MRD).
Despite advances in breast cancer detection and treatment, 30% of patients diagnosed with the disease will ultimately recur. Research indicates that seed cells—Minimal Residual Disease (MRD)—from the primary breast tumor can survive standard treatment and enter a dormant or sleeping phase. New technologies can identify and measure circulating tumor cells (CTCs), tumor cell fragment DNA (ctDNA), and dormant disseminated tumor cells (DTCs) in the blood and bone marrow.
The funds will support Dr. DeMichele and her team as they work to advance critical research on screening for and developing new ways of treating microscopic Minimal Residual Disease (MRD) in breast cancer survivors. MRD comprises the cells that ultimately lead to development of incurable metastatic breast cancer in organs and bones.